TREAT-HAP study of baricitinib for hospital-acquired pneumonia with a proinflammatory phenotype

Phase 3, randomised trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Baricitinib plus standard of care with Standard of care alone (2 arms). Primary endpoints: Clinical cure at test-of-cure visit and All-cause mortality at Day 28. Planned start Jun 2023; status: withdrawn.